Results 11 to 20 of about 8,380,026 (270)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia. [PDF]

Dermatology, 2023
Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz syndrome [G-G Syn]) treated with vismodegib in routine ...
Mesti T, Sever M, Ocvirk J.
europepmc   +6 more sources

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. [PDF]

J Eur Acad Dermatol Venereol
Resistència secundària; Carcinoma basocel·lular localment ...
Muñoz Couselo E, Berking C, Baurain JF, Martelli S, Arntz R, Savoia P.   +5 more
europepmc   +7 more sources

Locally advanced basal cell carcinoma: Real‐life data with sonidegib [PDF]

Dermatologic Therapy, 2022
In recent years, the category of hedgehog pathway inhibitor (HHI) has shown great results in patients with advanced basal cell carcinoma (aBCC), but few real-life data on efficacy and safety profile of sonidegib are available. We report our management of locally advanced BCCs (laBCCs) with sonidegib, also describing the favorable response of locally ...
Ludovica Toffoli, Claudio Conforti, Enrico Zelin, Roberta Vezzoni, Marina Agozzino, Nicola di Meo, Iris Zalaudek   +6 more
openaire   +4 more sources

Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma

Acta Dermato-Venereologica
Cutaneous basal cell carcinoma (BCC) is a primarily indolent tumour that is easily cured. However, locally advanced BCC (laBCC) and metastatic BCC can have a poor prognosis.
Anna A.J.H. Zwanenburg, Winan J. Van Houdt, A. Marjolein Schrijver, Willem H. Schreuder, Michel W. J. M. Wouters, Elsemieke I. Plasmeijer   +5 more
doaj   +4 more sources

Vismodegib: The Proof of Concept in Basal Cell Carcinoma

Clinical Medicine Insights: Oncology, 2014
Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases.
Narjiss Berrada, Siham Lkhoyali, Hind Mrabti, Hassan Errihani   +3 more
doaj   +2 more sources

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

Biologics: Targets & Therapy, 2015
Leslie A Fecher,1,3 William H Sharfman2 1Department of Internal Medicine and Dermatology, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA; 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA ...
Fecher LA, Sharfman WH
doaj   +1 more source

A multicenter real-world analysis of first-line systemic monotherapy for locally advanced basal cell carcinoma [PDF]

JAAD Case Reports, 2023
Morgan K. Groover, BS, Neha Gupta, MD, MPH, Emily Granger, BS, Fadi Murad, MD, MPH, Vernon J. Forrester, MD, Emily J. Anstadt, MD, PhD, William Su, MD, Lauren Heusinkveld, MD, John N. Lukens, MD, Ann W. Silk, MD, MS, Allison T. Vidimos, RPh, MD, Jonathan D. Schoenfeld, MD, MPH, Shlomo A. Koyfman, MD, Emily S. Ruiz, MD, MPH   +13 more
doaj   +2 more sources

Neoadjuvant Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma: Insights from Two Real-world Cases [PDF]

Acta Dermato-Venereologica
Paolo Antonetti, Ettore Lupi, Irene Tucceri Cimini, Maria Esposito, Maria Concetta Fargnoli   +4 more
doaj   +2 more sources

Induction Systemic Therapy Followed by Response-Adapted Consolidative Radiation in Locally Advanced Non-Melanoma Skin Cancer: A Retrospective Case Series [PDF]

Current Oncology
Background: There exists an unmet clinical need to define definitive management strategies for patients with locally advanced non-melanoma skin cancers (NMSC), particularly if not amenable to surgical resection.
Poorva Vaidya, Tali Azenkot, John Bliamptis, Mitchell Toby Victor, Anna Dornisch, Jennifer Chang, Parag Sanghvi, Theresa Guo, Soo J. Park   +8 more
doaj   +2 more sources

Updates in Management of Locally and Regionally Advanced Basal Cell Carcinoma

Surgical Clinics of North America
Basal cell carcinoma (BCC) is a slow-growing skin cancer that tends to remain localized but that can occasionally grow extensively and penetrate deeper tissues (locally advanced BCC [laBCC]). The first line of treatment for laBCC is surgical excision, but when resection is not possible systemic therapies such as Hedgehog pathway inhibitors or immune ...
Kristel, Lourdault, Brett, Crosby, Jillian, McCabe, Richard, Essner   +3 more
openaire   +3 more sources